<MedlineCitation Status="Completed">
<MedlineID>10011549</MedlineID>
<PMID>369623</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3223</ISSN>
<JournalIssue>
<Volume>14</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients.</ArticleTitle>
<Pagination>
<MedlinePgn>53-67</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>L-5-Hydroxytryptophan (L-5HTP) and the peripheral decarboxylase inhibitor carbidopa were administered to chronic schizophrenic patients in three separate experiments using a double-blind placebo-controlled crossover design. The three experiments were: (i) L-5HTP administration to 15 patients who had been withdrawn from all neuroleptic medication; (ii) L-5HTP administration to seven patients maintained on haloperidol; (iii) L-5HTP administration to nine patients maintained on chlorpromazine. Although the groups were diagnostically homogeneous, individual responses were highly variable. Considering each group as a whole, the only significant changes in rated psychosis consisted of an increase in the first group consequent to coming off neuroleptic medication and an increase in psychosis scores associated with adding L-5HTP to chlorpromazine. Neuroleptics apparently sensitize the central nervous system to the effects of L-5HTP loading. Acute exacerbations of psychosis induced by L-5HTP can be reversed by neuroleptics. Our experience does not give encouragement to the hypothesis that schizophrenic illnesses arise consequent to a deficit of serotonergic function that can be treated by giving a serotonin precursor in pharmacological quantities.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Bigelow</LastName>
<ForeName>L B</ForeName>
<Initials>LB</Initials>
</Author>
<Author>
<LastName>Walls</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author>
<LastName>Gillin</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author>
<LastName>Wyatt</LastName>
<ForeName>R J</ForeName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Controlled Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Biol Psychiatry</MedlineTA>
<NlmUniqueID>0213264</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>38821-49-7</RegistryNumber>
<NameOfSubstance>Carbidopa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-53-3</RegistryNumber>
<NameOfSubstance>Chlorpromazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>52-86-8</RegistryNumber>
<NameOfSubstance>Haloperidol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-69-9</RegistryNumber>
<NameOfSubstance>5-Hydroxytryptophan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>5-Hydroxytryptophan</DescriptorName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adolescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Carbidopa</DescriptorName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Chlorpromazine</DescriptorName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Clinical Trials</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Haloperidol</DescriptorName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Schizophrenia</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
